RCT2100 clinical trials

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

This study is testing a new inhaled medicine, RCT2100, for cystic fibrosis. It will first check if it's safe for healthy people, then for people with CF, sometimes alongside other CF treatments. We aim to understand its safety and how the body handles it.